UroToday1d
APCCC Diagnostics 2025: What Imaging Should You Use in Case of Suspected Metastases?
(UroToday.com) Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics 2025 held in Lugano, Switzerland was host to a session addressing the contemporary management of metastatic prostate ...
UroToday1d
APCCC Diagnostics 2025: Risk Stratification Using a Genomic Classifier for Localized Prostate Cancer: What Is the Added Value?
(UroToday.com) The 2025 APCCC Diagnostics annual meeting featured a session on how to stage and estimate risk for prostate cancer and a presentation by Dr. Daniel Spratt discussing the added value of ...
UroToday1d
ASCO GU 2025: Final Overall Survival and New ctDNA Analysis in MET-Driven Advanced Papillary Renal Cancer (CALYPSO)
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Annual Symposium held in San Francisco, CA between February 13–15, 2025 was host to a renal cell cancer rapid ...
UroToday1d
ASCO GU 2025: Real-World Outcomes of Nadofaragene Firadenovec in BCG-Unresponsive NMIBC
(UroToday.com) The 2025 GU ASCO annual meeting featured a urothelial carcinoma session and a presentation by Jacob Moyer discussing real-world outcomes of nadofaragene firadenovec in BCG-unresponsive ...
UroToday1d
First Real-World Outcomes Data for ADSTILADRIN® (nadofaragene firadenovec-vncg) to be Presented at 2025 ASCO Genitourinary Cancers Symposium
Independent experience at three Mayo Clinic sites and real-world outcomes data with ADSTILADRIN in patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder ...
UroToday1d
AUA 2020: AUA Guidelines Case-Based Panel Discussion: Bladder Cancer (Non-Muscle and Muscle Invasive)
(UroToday.com) At the AUA 2020 virtual annual meeting, Sam Chang, MD, MBA, moderated a case-based panel discussion on both non-muscle and muscle-invasive bladder cancer. Areas of focus for this ...
UroToday1d
SES AUA 2025: Oncologic Efficacy of Reduced versus Standard-Dose BCG for NMIBC
(UroToday.com) The 2025 SESAUA annual meeting featured a bladder cancer session and a presentation by Dr. Meredith Bernhard discussing the oncologic efficacy of reduced versus standard-dose BCG for ...
UroToday3d
Advanced Prostate Cancer Videos
Neoadjuvant Therapy for Men with High Risk Disease Prior to Prostatectomy - Mary-Ellen Taplin ...
UroToday3d
The Optimal Treatment for Gleason Score 9-10 Prostate Cancer
Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...
UroToday4d
ADSTILADRIN® in Patients With High-Risk, BCG Unresponsive NMIBC
The 2024 ESMO Annual Congress was host to the session Updates in the management of advanced renal cell carcinoma. Dr. Teresa Alonso Gordoa discussed systemic treatment options for the management of ...
UroToday4d
SES AUA 2025: Artificial Intelligence Applications in Prostate Cancer Diagnosis and Treatment
Saikali S, Khosravi P, Gamal A, et al. MP07-02 Detection of Prostate Cancer Extracapsular Extension with MRI Using Deep Learning Methods. J Urol. 2024 May;211 (5S):e105.